Drug Regulation in the United States and the United Kingdom: The Depo-Provera Story
Authors:
- 1 June 1987
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 106 (6) , 886-891
Abstract
In 1984, both the United Kingdom and the United States received recommendations from panels of experts specifically convened to consider the merits of Depo-Provera (depot medroxyprogesterone acetate [DMPA]) as a long-term contraceptive agent. This study compares the final reports written by these panels. We explore why, despite access to essentially the same data, the U.K. panel recommended marketing approval but the U.S. Public Board of Inquiry did not. We conclude that differing national policies helped shape the interpretation of the data and thus the divergent outcomes.Keywords
This publication has 5 references indexed in Scilit:
- Panel Says Depo-Provera Not Proved SafeScience, 1984
- Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safetyClinical Pharmacology & Therapeutics, 1984
- The Estrogen Replacement Controversy in the USA and UK: Different Answers to the Same Question?Social Studies of Science, 1984
- The drug lag revisited: Comparison by therapeutic area of patterns of drugs marketed in the United States and Great Britain from 1972 through 1976Clinical Pharmacology & Therapeutics, 1978
- Introduction of new therapeutic drugs in the United States and Great Britain: An international comparisonClinical Pharmacology & Therapeutics, 1973